Amsterdam Molecular Therapeutics Completes Advance Distribution of uniQure Depositary Receipts to AMT Shareholders

AMSTERDAM, April 26, 2012 /PRNewswire/ --

Amsterdam Molecular Therapeutics (AMT) Holding N.V. in liquidation (in liquidatie) (Euronext: AMT), today announces that the advance distribution of uniQure depositary receipts to AMT shareholders was completed today. It is not expected that will be any further (final) distributions made to AMT shareholders.

More information on the advance distribution and the further upcoming events and steps in the AMT's liquidation process and delisting and the timing thereof can be found in the overview of the key transaction elements and the transaction timetable that is available via AMT's website and in AMT's press releases of 6 and 17 April 2012.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.